Stock BMY BRISTOL-MYERS SQUIBB COMPANY
Add to a list
To use this feature you must be a member
Log inSign up
PDF Report : Bristol-Myers Squibb Company

Bristol-Myers Squibb Company Stock price

Equities

BMY

US1101221083

Pharmaceuticals

Market Closed - Nyse
Other stock markets
 16:00:02 2023-12-08 EST 		Intraday chart for Bristol-Myers Squibb Company 5-day change 1st Jan Change
50.31 USD +0.30% +0.42% -30.08%
12-07 Global markets live: AbbVie, McDonald's, Apple, AMD, Alphabet...
12-07 Are rate cuts are coming early next year?

Financials

Sales 2023 * 44.79B 60.85B Sales 2024 * 45.9B 62.36B Capitalization 102B 139B
Net income 2023 * 7.96B 10.82B Net income 2024 * 7.29B 9.9B EV / Sales 2023 *
2,84x
Net Debt 2023 * 24.94B 33.88B Net Debt 2024 * 16.87B 22.92B EV / Sales 2024 *
2,60x
P/E ratio 2023 *
13,3x
P/E ratio 2024 *
12,6x
Employees 34,300
Yield 2023 *
4,53%
Yield 2024 *
4,74%
Free-Float 69.53%
More Fundamentals * Assessed data

Chart Bristol-Myers Squibb Company

Dynamic Chart

Latest news about Bristol-Myers Squibb Company

Global markets live: AbbVie, McDonald's, Apple, AMD, Alphabet...
Are rate cuts are coming early next year?
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday MT
S&P, Nasdaq eye higher open on Alphabet boost, payrolls data in focus RE
Bristol-Myers Squibb Adds $3 Billion to Buyback Program MT
Bristol-Myers Squibb Says Phase 3 Trial of Opdivo and Yervoy Achieved Primary Endpoint MT
Bristol Myers: share buyback program expanded CF
Bristol-Myers Squibb Company Announces Phase 3 Checkmate -8Hw Trial Evaluating Opdivo Plus Yervoy Compared to Chemotherapy in Microsatellite Instability?High or Mismatch Repair Deficient Metastatic Colorectal Cancer Meets Primary CI
Bristol Myers Adds $3 Billion to Stock Buyback Program DJ
Bristol Myers: 5% dividend increase CF
Bristol-Myers Squibb Raises Quarterly Dividend to $0.60 a Share from $0.57, Payable on Feb. 1 to Shareholders as of Jan. 5 MT
Bristol Myers Squibb Raises Dividend 5.3%, to 60 Cents DJ
Bristol-Myers Squibb Company Declares Quarterly Dividend on Common Stock, Payable on February 1, 2024 CI
UniCredit seeks new chair candidate by early 2024, sources say RE
IMIDomics and Bristol Myers Squibb Expand Long-Standing Partnership to Advance Immune-Mediated Inflammatory Diseases CI
More news

Analyst Recommendations on Bristol-Myers Squibb Company

Cantor Fitzgerald Downgrades Bristol-Myers Squibb to Neutral From Overweight, Cuts Price Target to $55 From $68 MT
Deutsche Bank Initiates Coverage on Bristol-Myers Squibb With Hold Rating, $55 Price Target MT
Daiwa Securities Downgrades Bristol-Myers Squibb to Neutral From Outperform, Adjusts Price Target to $54 From $68 MT
Berenberg Bank Adjusts Bristol-Myers Squibb Price Target to $60 From $76, Maintains Hold Rating MT
Goldman Sachs Adjusts Price Target on Bristol-Myers Squibb to $69 From $81, Maintains Buy Rating MT
More recommendations

Press releases Bristol-Myers Squibb Company

Bristol Myers Squibb Presents Primary Efficacy and Safety Analysis of the Phase 3 COMMANDS Trial of Reblozyl for Treatment of Anemia in Erythropoiesis Stimulating Agent-Naïve Patients with Lower-Risk Myelodysplastic Syndromes at ASH 2023 BU
Bristol Myers Squibb Announces Phase 3 CheckMate -8HW Trial Evaluating Opdivo Plus Yervoy Compared to Chemotherapy in Microsatellite Instability-High or Mismatch Repair Deficient Metastatic Colorectal Cancer Meets Primary AQ
Bristol Myers Squibb Announces Phase 3 CheckMate -8HW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Compared to Chemotherapy in Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer Meets Primary... BU
Bristol Myers Squibb Announces Additional $3 Billion Share Repurchase Authorization BU
Bristol Myers Squibb Announces Dividend Increase BU
More press releases

News in other languages on Bristol-Myers Squibb Company

Bristol Myers Squibb : annonce des rachats d'actions pour 3 milliards de dollars de plus
Wall Street ouvre en hausse avec Alphabet et avant l'emploi américain
Bristol Myers verhoogt aandeleninkoop fors
Bristol Myers : gonflement du programme de rachat d'actions
Bristol Myers : augmentation de 5% du dividende
More news

Quotes and Performance

1 day+0.30%
1 week+0.42%
Current month+1.88%
1 month-4.03%
3 months-17.28%
6 months-22.97%
Current year-30.08%
More quotes

Highs and lows

1 week
49.56
Extreme 49.56
51.00
1 month
48.25
Extreme 48.252
51.74
Current year
48.25
Extreme 48.252
75.18
1 year
48.25
Extreme 48.252
79.36
3 years
48.25
Extreme 48.252
81.44
5 years
42.48
Extreme 42.48
81.44
10 years
42.48
Extreme 42.48
81.44
More quotes

Managers and Directors - Bristol-Myers Squibb Company

Managers TitleAgeSince
Christopher Boerner CEO
 Chief Executive Officer 52 2015
Giovanni Caforio CHM
 Chairman 58 1999
David Elkins DFI
 Director of Finance/CFO 54 2019
Members of the board TitleAgeSince
Phyllis R. Yale BRD
 Director/Board Member 65 2019
Peter Arduini BRD
 Director/Board Member 58 2016
Derica Rice BRD
 Director/Board Member 58 2020
More insiders

ETFs positioned on Bristol-Myers Squibb Company

Name Weight AuM 1st Jan change Investor Rating
AGF U.S. MARKET NEUTRAL ANTI-BETA FUND - USD ETF AGF U.S. Market Neutral Anti-Beta Fund - USD
12.97% 323 M€ -8.82% -
FIRST TRUST NASDAQ PHARMACEUTICALS ETF - USD ETF First Trust Nasdaq Pharmaceuticals ETF - USD
6.42% 18 M€ -7.62% -
HORIZON KINETICS MEDICAL ETF - USD ETF Horizon Kinetics Medical ETF - USD
6.03% 16 M€ 0.00% -
HARVEST HEALTHCARE LEADERS INCOME ETF - CAD HEDGED ETF Harvest Healthcare Leaders Income ETF - CAD Hedged
5.00% 820 M€ -4.99% -
More ETFs positioned on Bristol-Myers Squibb Company

Quotes

Date Price Change Volume
23-12-08 50.31 +0.30% 10,123,073
23-12-07 50.16 +0.56% 14,710,574
23-12-06 49.88 -0.70% 13,839,803
23-12-05 50.23 +0.50% 12,659,509
23-12-04 49.98 -0.24% 14,238,572

Delayed Quote Nyse, December 08, 2023 at 04:00 pm

More quotes

Company Profile

More about the company

Income Statement Evolution

More financial data

Ratings for Bristol-Myers Squibb Company

Trading Rating :
Investor Rating :
ESG Refinitiv :
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
50.31USD
Average target price
64.13USD
Spread / Average Target
+27.48%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
BRISTOL-MYERS SQUIBB COMPANY Stock Bristol-Myers Squibb Company
-30.08% 102 B $
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+63.47% 538 B $
NOVO NORDISK A/S Stock Novo Nordisk A/S
+42.56% 430 B $
JOHNSON & JOHNSON Stock Johnson & Johnson
-12.58% 372 B $
ABBVIE INC. Stock AbbVie Inc.
-7.63% 264 B $
MERCK & CO., INC. Stock Merck & Co., Inc.
-6.49% 263 B $
ROCHE HOLDING AG Stock Roche Holding AG
-12.81% 232 B $
NOVARTIS AG Stock Novartis AG
+1.35% 198 B $
ASTRAZENECA PLC Stock AstraZeneca PLC
-9.77% 197 B $
PFIZER, INC. Stock Pfizer, Inc.
-43.83% 163 B $
Other Pharmaceuticals
  1. Stock
  2. Equities
  3. Stock Bristol-Myers Squibb Company - Nyse
Secure and Increase the Performance of your Investments with our Team of Experts at your Side
Securing my Investments
fermer
Etats-Unis

MarketScreener is also available in this country: United States.

Switch edition
Stay in the current country edition